BRAF mutation in the elderly submitted to thyroidectomy.

OBJECTIVE To evaluate the frequency of the BRAF V600E mutation in patients over 65 years of age undergoing thyroidectomy, correlating its presence or absence with the different histologic lesions, their variants and with prognostic factors of papillary carcinoma. METHODS We evaluated 85 patients over 65 years of age who underwent thyroidectomy, analyzing the BRAF V600E mutation by RT-PCR performed after DNA extraction from the paraffin blocks. RESULTS The study detected the presence or absence of BRAF V600E mutation in 47 patients (55.3%). Among the 17 papillary carcinomas studied, seven had the mutation (41.2%). There was a statistical association between the presence of this mutation and the classic variant of papillary carcinoma, and a trend of association with thyroid extravasation. CONCLUSION BRAF mutation in the elderly is also exclusive of papillary carcinoma and is often significant. Furthermore, it is related to the classic variant and possibly to thyroid extravasation.

[1]  M. Melo,et al.  Mutação BRAF em pacientes idosos com carcinoma papilífero , 2011 .

[2]  M. Ladanyi,et al.  Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. , 2009, Cancer research.

[3]  J. Cerutti,et al.  High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas , 2009, Cancer.

[4]  M. Hirokawa,et al.  BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. , 2009, Endocrine journal.

[5]  J. Cerutti,et al.  Seven-year follow-up of a juvenile female with papillary thyroid carcinoma with poor outcome, BRAF mutation and loss of expression of iodine-metabolizing genes. , 2008, Arquivos brasileiros de endocrinologia e metabologia.

[6]  A. Pinchera,et al.  BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. , 2008, The Journal of clinical endocrinology and metabolism.

[7]  D. Spandidos,et al.  RKIP and BRAF aberrations in human nasal polyps and the adjacent turbinate mucosae. , 2008, Cancer letters.

[8]  M. Santoro,et al.  Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. , 2007, The Journal of clinical endocrinology and metabolism.

[9]  Electron Kebebew,et al.  The Prevalence and Prognostic Value of BRAF Mutation in Thyroid Cancer , 2007, Annals of surgery.

[10]  B. Jarzab,et al.  Differentiated thyroid cancer in children and adults: same or distinct disease? , 2007, Hormones.

[11]  E. Puxeddu,et al.  Clinical prognosis in BRAF-mutated PTC. , 2007, Arquivos brasileiros de endocrinologia e metabologia.

[12]  H. Namba,et al.  No evidence of ARAF, CRAF and MET mutations in BRAFT1799A negative human papillary thyroid carcinoma. , 2006, Endocrine journal.

[13]  Jung Hun Song,et al.  Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. , 2006, The Journal of clinical endocrinology and metabolism.

[14]  A. Pinchera,et al.  Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. , 2006, Endocrine-related cancer.

[15]  R. Marais,et al.  Is BRAF the Achilles' Heel of Thyroid Cancer? , 2006, Clinical Cancer Research.

[16]  M. A. García-Cabezas,et al.  The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. , 2006, Endocrine-related cancer.

[17]  T. Fahey.  Type and Prevalence of BRAF Mutations Are Closely Associated With Papillary Thyroid Carcinoma Histotype and Patients' Age But Not With Tumour Aggressiveness , 2006 .

[18]  P. Ladenson,et al.  BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. , 2005, The Journal of clinical endocrinology and metabolism.

[19]  M. Xing,et al.  BRAF mutation in thyroid cancer. , 2005, Endocrine-related cancer.

[20]  Lei Zhang,et al.  Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. , 2005, Cancer research.

[21]  J. Fagin.  How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. , 2004, The Journal of endocrinology.

[22]  D. Sidransky,et al.  BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment , 2004, Modern Pathology.

[23]  J. Fagin.  Challenging dogma in thyroid cancer molecular genetics--role of RET/PTC and BRAF in tumor initiation. , 2004, The Journal of clinical endocrinology and metabolism.

[24]  M. Santoro,et al.  BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas. , 2004, The Journal of clinical endocrinology and metabolism.

[25]  Masahiro Ito,et al.  Low frequency of BRAFT1796A mutations in childhood thyroid carcinomas. , 2004, The Journal of clinical endocrinology and metabolism.

[26]  P. Beck‐Peccoz,et al.  BRAF mutations in an Italian cohort of thyroid cancers , 2004, Clinical endocrinology.

[27]  V. Trovisco,et al.  BRAF mutations are associated with some histological types of papillary thyroid carcinoma , 2004, The Journal of pathology.

[28]  M. Nikiforova,et al.  BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. , 2003, The Journal of clinical endocrinology and metabolism.

[29]  P. Gattuso,et al.  Genomic DNA Extraction and PCR Amplification of Exon 15 of the BRAF Gene and Exons 1 and 2 of the NRAS Gene , 2003 .

[30]  Yuri E Nikiforov,et al.  High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. , 2003, Cancer research.